- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03726996
Desipramine in Infantile Neuroaxonal Dystrophy (INAD).
Novel Off-label Use of Desipramine in Infantile Neuroaxonal Dystrophy: Targeting the Sphingolipid Metabolism Pathway to Reduce Accumulation of Ceramide.
This is a research study to find out if clinically prescribed desipramine is effective at improving the symptoms and slowing the progression of Infantile Neuroaxonal Dystrophy (INAD) in affected children.
Participants will receive an initial oral dose of study drug once a day. This dose may be changed depending on response to study drug Clinically collected data will be recorded for up to 5 years. Investigators will also ask for participant permission to obtain a sample of child's skin biopsy from unused clinical sample previously collected for standard of care.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
To be eligible participants must be able to swallow tablets The study drug is to be taken once daily Schedule of events. Day 0 - ECG and blood tests (4 ml or ¾ teaspoon) Day 3 - ECG and blood tests (4 ml or ¾ teaspoon) Day 7 - ECG and blood tests (4 ml or ¾ teaspoon) Weeks 2, 3, 4, 8 & 12. ECG and blood tests (4 ml or ¾ teaspoon) Every 3 months for up to 5 years.
.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Health Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 03-17years.
- Any gender
- Confirmed homozygotes or compound heterozygotes of pathogenic mutation variant(s) in PLA2G6
- Confirmed homozygotes of pathogenic mutation in PLA2G6
- Documentation of clinical presentation (signs and symptoms of neurodegenerative process) of INAD
Exclusion Criteria:
- Patient has sign and symptom suggesting an ongoing acute or chronic illness such as fever of unknown origin or infection.
- Patient has a second genetic condition
- Parents are unable or unwilling to return for continued care for up to 12 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Children with INAD
Infantile neuroaxonal dystrophy (INAD) is an extremely rare autosomal recessive neurodegenerative disorder that has grave clinical outcome and significant morbidity and mortality.
|
Study drug (desipramine) provided in tablet form to be taken daily.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Gross Motor Function as Measured by Gross Motor Function Measure (GMFM-66)
Time Frame: Baseline, 3, 6, 9, and 12 months
|
The Gross Motor Function Measure (GMFM-66) is a 66 item standardized observational instrument designed and validated to measure change in gross motor function over time in children with cerebral palsy.
Items are ordered in terms of difficulty and a unit of change has the same meaning throughout the scale ranging from 0 to 100.
0 = does not initiate, 1 = initiates, 2 = partially completes, 3 = completes.
Scoring the GMFM-66 requires the use of a computer program called the Gross Motor Ability Estimator (GMAE).
Individual item scores are entered and a mathematical algorithm calculates an interval level total score.
The total score is an estimate of the child's gross motor function.
|
Baseline, 3, 6, 9, and 12 months
|
Change in Motor Function as Measured by Quick Motor Function Test (QMFT)
Time Frame: Baseline, 3, 6, 9, and 12 months
|
The Quick Motor Function Test (QMFT) is a 16 item, psychometrically robust outcome assessment, validated in children and adults with Pompe disease (a lysosomal storage disorder characterized by progressive muscle weakness).
This motor function test observes performance and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4).
If items can be performed on both left and right extremities, the right side is taken.
A total score is obtained by adding the scores of all items.
The total score ranges between 0 and 64 points.
A higher score correlates with greater motor function.
|
Baseline, 3, 6, 9, and 12 months
|
Change in Cognitive Function as Measured by the Vineland Adaptive Behavioral Scale
Time Frame: Baseline, 3, 6, 9, and 12 months
|
The Vineland-3 is a standardized measure of adaptive behavior--the things that people do to function in their everyday lives.
It is a norm-based instrument that compares the examinee's adaptive functioning in four domains: Communication, Daily Living Skills, Socialization and Motor Skills to that of others of the same age.
A composite score of adaptive behavior is calculated that summarizes the individual's performance across all four domains.
|
Baseline, 3, 6, 9, and 12 months
|
Number of Participants With Change in Q-T Interval on ECG
Time Frame: Baseline, 3, 6, 9, and 12 months
|
Evidence of ECG changes, specifically, prolonged Q-T interval in response to study drug.
The Q-T interval is the time from the start of the Q wave to the end of the T wave.
It represents the time taken for ventricular depolarisation and repolarisation, effectively the period of ventricular systole from ventricular isovolumetric contraction to isovolumetric relaxation.
Participants with a prolonged Q-T interval at any timepoint is reported.
|
Baseline, 3, 6, 9, and 12 months
|
Number of Participants With Abnormal Transaminase Values
Time Frame: Baseline, 3, 6, 9, and 12 months
|
Transaminase values as measured by serum alanine transaminase (ALT) and aspartate transaminase (AST).
Participants with abnormal transaminase values at any timepoint is reported.
|
Baseline, 3, 6, 9, and 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yong-hui Jiang, MD, Duke University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neuroaxonal Dystrophies
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Antidepressive Agents, Tricyclic
- Adrenergic Uptake Inhibitors
- Desipramine
Other Study ID Numbers
- Pro00100799
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infantile Neuroaxonal Dystrophy
-
Retrotope, Inc.CompletedNeuroaxonal Dystrophy, InfantileEgypt, China, Saudi Arabia, India, Tunisia
-
Retrotope, Inc.Active, not recruitingInfantile Neuroaxonal DystrophyUnited States
-
Retrotope, Inc.CompletedInfantile Neuroaxonal Dystrophy | INADUnited States
-
University Hospital, Clermont-FerrandEnrolling by invitationNeuroaxonal Dystrophy, AtypicalFrance
-
Assiut UniversityRecruiting
-
SOFAR S.p.A.CompletedInfantile Colic | Colic, InfantileItaly
-
Assistance Publique - Hôpitaux de ParisOSO-AIRecruiting
-
Hospital San BartolomeInstituto de Investigacion de las Alteraciones del Crecimiento, Desarrollo...Unknown
-
Yuzuncu Yıl UniversityIstanbul University - Cerrahpasa (IUC)Recruiting
-
Federico II UniversityCompleted
Clinical Trials on Desipramine
-
SandozCompleted
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Joel NealTerminatedNeuroendocrine Tumors | Small Cell Lung Cancer (SCLC)United States
-
Boehringer IngelheimCompleted
-
SandozCompleted
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedRefractory Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma | DS (Durie/Salmon) Stage I Plasma Cell MyelomaUnited States
-
Astellas Pharma IncCompletedHealthy Subjects | Pharmacokinetics of MirabegronFrance
-
Dartmouth-Hitchcock Medical CenterUniversity of South Carolina; University of Massachusetts, Worcester; Michigan...CompletedAlcoholism | Schizophrenia | Dual DiagnosisUnited States